Announced details
Healthcare, pharmaceuticals, overseas expansion, business partnerships
The company’s U.S. subsidiary
The company’s U.S. subsidiary. The Chairman is Neil W. Gibson, Ph.D. He is described as a person who has led pharmaceutical research and development, primarily in cancer treatment, for more than 30 years. Details of its location, capital, year of establishment and business activities are Not disclosed.
Hibiya Mitsui Conference, 8th floor (event venue)
In this announcement the company addresses none of Contract Value / Offering price / Impact on Business Performance.
| Item | Details |
|---|---|
| Counterparty | Nano Holdings US, LLC |
| Counterparty overview | The company’s U.S. subsidiary. The Chairman is Neil W. Gibson, Ph.D. He is described as a person who has led pharmaceutical research and development, primarily in cancer treatment, for more than 30 years. Details of its location, capital, year of establishment and business activities are Not disclosed. |
| Relationship with the Company | The company’s U.S. subsidiary |
| Launch date | 30 June 2026 (scheduled; event date) |
| Applicable area | Healthcare, pharmaceuticals, overseas expansion, business partnerships |
| Location | Hibiya Mitsui Conference, 8th floor (event venue) |
| Location scale | Admission is limited to the first 100 people |
Items this document does not state (11)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.To communicate why overseas investors are interested in Japanese companies, how Japanese companies’ technologies and business assets are valued in global markets, and opportunities to build ties with global capital.